Show simple item record

dc.contributor.authorFeinstein, A
dc.contributor.authorAmato, MP
dc.contributor.authorBrichetto, G
dc.contributor.authorChataway, J
dc.contributor.authorChiaravalloti, ND
dc.contributor.authorCutter, G
dc.contributor.authorDalgas, U
dc.contributor.authorDeLuca, J
dc.contributor.authorFarrell, R
dc.contributor.authorFeys, P
dc.contributor.authorFilippi, M
dc.contributor.authorFreeman, J
dc.contributor.authorInglese, M
dc.contributor.authorMeza, C
dc.contributor.authorMotl, RW
dc.contributor.authorRocca, MA
dc.contributor.authorSandroff, BM
dc.contributor.authorSalter, A
dc.date.accessioned2022-11-16T15:16:33Z
dc.date.issued2022-12
dc.identifier.issn0340-5354
dc.identifier.issn1432-1459
dc.identifier.urihttp://hdl.handle.net/10026.1/19980
dc.description.abstract

Objective: An earlier follow-up study from the CogEx rehabilitation trial showed little change in symptoms of depression, anxiety and psychological distress during the first COVID-19 lockdown compared to pre-pandemic measurements. Here we provide a second follow-up set of behavioral data on the CogEx sample. Methods: This was an ancillary, longitudinal follow-up study in CogEx, a randomized controlled trial of exercise and cognitive rehabilitation in people with progressive MS involving 11 centres in North America and Europe. Only individuals impaired on the Symbol Digit Modalities Test (SDMT) were included. Participants repeated the COVID Impact survey administered approximately a year later and completed self-report measures of depression, anxiety and MS symptoms that had been obtained at the trial baseline and during the first COVID Impact survey. Participants who completed the second COVID Impact follow up were included. To identify predictors of the participants’ ratings of their mental and physical wellbeing, step-wise linear regression was conducted. Results: Of the 131 participants who completed the first COVID impact survey, 74 participants completed the second follow-up survey (mean age 52 (SD=6.4) years, 62.2% female, mean disease duration 16.4 (SD=9.0) years, median EDSS 6.0). Pandemic restrictions prevented data collection from sites in Denmark and England (n=57). The average time between measurements was 11.4 (SD=5.56) months. There were no significant differences in age, sex, EDSS, disease course and duration between those who participated in the current follow-up study (n=74) and the group that could not (n=57). One participant had COVID in the time between assessments. Participants now took a more negative view of their mental/psychological wellbeing (p=.0001), physical wellbeing (p=.0009) and disease course (p=.005) compared to their last assessment. Depression scores increased on the HADS-depression scale (p = .01) and now exceeded the clinically significant threshold of ≥ 8.0 for the first time. Anxiety scores on the HADS remained unchanged. Poorer mental wellbeing was predicted by HADS depression scores (p=.012) and a secondary-progressive disease course (p=.0004). Conclusions: A longer follow-up period revealed the later onset of clinically significant depressive symptoms on the HADS and a decline in self-perceptions of mental and physical wellbeing associated with the COVID-19 pandemic relative to the first follow-up data point.

dc.format.extent6202-6210
dc.format.mediumPrint-Electronic
dc.languageen
dc.language.isoeng
dc.publisherSpringer Science and Business Media LLC
dc.subjectCOVID-19
dc.subjectProgressive multiple sclerosis
dc.subjectMental well-being
dc.subjectLongitudinal
dc.subjectDepression
dc.subjectAnxiety
dc.titleThe late onset of emotional distress in people with progressive multiple sclerosis during the Covid-19 pandemic: longitudinal findings from the CogEx study
dc.typejournal-article
dc.typeArticle
plymouth.author-urlhttps://www.ncbi.nlm.nih.gov/pubmed/35939096
plymouth.issue12
plymouth.volume269
plymouth.publisher-urlhttp://dx.doi.org/10.1007/s00415-022-11295-5
plymouth.publication-statusPublished
plymouth.journalJournal of Neurology
dc.identifier.doi10.1007/s00415-022-11295-5
plymouth.organisational-group/Plymouth
plymouth.organisational-group/Plymouth/Faculty of Health
plymouth.organisational-group/Plymouth/Faculty of Health/School of Health Professions
plymouth.organisational-group/Plymouth/REF 2021 Researchers by UoA
plymouth.organisational-group/Plymouth/REF 2021 Researchers by UoA/UoA03 Allied Health Professions, Dentistry, Nursing and Pharmacy
plymouth.organisational-group/Plymouth/Research Groups
plymouth.organisational-group/Plymouth/Research Groups/Institute of Health and Community
plymouth.organisational-group/Plymouth/Research Groups/Plymouth Institute of Health and Care Research (PIHR)
plymouth.organisational-group/Plymouth/Users by role
plymouth.organisational-group/Plymouth/Users by role/Academics
plymouth.organisational-group/Plymouth/Users by role/Researchers in ResearchFish submission
dc.publisher.placeGermany
dcterms.dateAccepted2022-07-13
dc.rights.embargodate2023-8-8
dc.identifier.eissn1432-1459
dc.rights.embargoperiodNot known
rioxxterms.versionofrecord10.1007/s00415-022-11295-5
rioxxterms.licenseref.urihttp://www.rioxx.net/licenses/all-rights-reserved
rioxxterms.licenseref.startdate2022-12
rioxxterms.typeJournal Article/Review


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record


All items in PEARL are protected by copyright law.
Author manuscripts deposited to comply with open access mandates are made available in accordance with publisher policies. Please cite only the published version using the details provided on the item record or document. In the absence of an open licence (e.g. Creative Commons), permissions for further reuse of content should be sought from the publisher or author.
Theme by 
Atmire NV